Tempus AI, Inc. (TEM) Earnings Call Analysis

NASDAQ · Healthcare · Health Information Services

Earnings Reports

• Tempus AI (TEM) Q2 2026: FDA Approvals Set Stage for $400M Revenue Uplift by 2028
  July 31, 2026
• Tempus AI (TEM) Q1 2026: Data Business Jumps 41% as Pharma Demand Deepens
  May 06, 2026
• Tempest (TEM) Q4 2025: Data Licensing Jumps 69% as AI-Driven Platform Pulls Ahead
  February 25, 2026
• Tempus AI (TEM) Q3 2025: Data Licensing Bookings Top $150M, Powering Durable Margin Turn
  November 05, 2025
• Tempest (TEM) Q2 2025: Genomics Revenue Soars 115% as Oncology Volumes Accelerate
  August 08, 2025
• Tempest (TEM) Q1 2025: Data Contracts Top $1B as Genomics Revenue Jumps 89%
  July 07, 2025

Browse all companies